Crinetics (CRNX) announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, once-daily, oral adrenocorticotropic hormone receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Crinetics announces first patient dosed in Phase 1/2 study of CRN09682
- Crinetics randomizes first patient in CAREFNDR trial
- Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals
- Crinetics price target raised to $45 from $40 at Goldman Sachs